The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
Open accessAbstract
Graft versus host disease (GVHD), mediated by donor T cells, is a significant source of morbidity and mortality following allogeneic stem cell transplantation. Mesenchymal stem cells (MSC) can successfully treat ongoing graft versus host disease, presumably due to their ability to suppress donor T cell proliferation. Little is known about the potential of MSC to prevent GVHD. Here we show that bone marrow‐isolated MSC can suppress the development of GVHD if given after donor T cell recognition of antigen. IFN‐γ was required to initiate MSC efficacy. Recipients of IFN‐γ–/– T cells did not respond to MSC treatment and succumbed to GVHD. MSC, pre‐treated with IFN‐γ, became immediately active and could suppress GVHD more efficiently than a fivefold‐greater number of MSC that were not activated. When given at the time of bone marrow transplantation, activated MSC could prevent GVHD mortality (100% survival, p=0.006). MSC activation was dependent on the magnitude of IFN‐γ exposure, with increased IFN‐γ exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC. See accompanying commentary: http://dx.doi.org/10.1002/eji.200838433
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Self-citationHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
Phinney, D. G., & Prockop, D. J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0637 · Cited by 1,908
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Cited by
Hass, R., Kasper, C., Böhm, S., & Jacobs, R. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-12 · Cited by 1,748
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Bernardo, M. E., & Fibbe, W. E. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.09.006 · Cited by 1,383
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018
Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives
Liang, X., Ding, Y., Zhang, Y., Tse, H.-F., & Lian, Q. (2014) · Cell Transplantation · doi:10.3727/096368913x667709 · Cited by 909
Advances in graft-versus-host disease biology and therapy
Blazar, B. R., Murphy, W. J., & Abedi, M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3212 · Cited by 880
Stem Cell Paracrine Actions and Tissue Regeneration
Baraniak, P. R., & McDevitt, T. C. (2010) · Regenerative Medicine · doi:10.2217/rme.09.74 · Cited by 843
Strioga, M., Viswanathan, S., Darinskas, A., Slaby, O., & Michalek, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0722 · Cited by 825
Zhang, Q., Shi, S., Liu, Y., Uyanne, J., Shi, Y., Shi, S., & Le, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902318 · Cited by 752
Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis
Akiyama, K., Chen, C., Wang, D., Xu, X., Qu, C., Yamaza, T., Cai, T., Chen, W., Sun, L., & Shi, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.007 · Cited by 705
François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694
English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03874.x · Cited by 676
How mesenchymal stem cells interact with tissue immune responses
Shi, Y., Su, J., Roberts, A. I., Shou, P., Rabson, A. B., & Ren, G. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.11.004 · Cited by 633
Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning
Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02837 · Cited by 572
Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders
Riazifar, M., Mohammadi, M. R., Pone, E. J., Yeri, A., Lässer, C., Segaliny, A. I., McIntyre, L. L., Shelke, G. V., Hutchins, E., Hamamoto, A., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01004 · Cited by 551
Mechanisms of mesenchymal stromal cell immunomodulation
English, K. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2012.56 · Cited by 518
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507
“MSC-mediated immunosuppression requires preliminary activation of the MSCs by immune cells through the secretion of the proinflammatory cytokine IFNγ, alone or together with TNFα, IL-1α or IL-1β [5,6].”
BackgroundUmbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility
Nagamura-Inoue, T. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i2.195 · Cited by 476
Krampera, M., Galipeau, J., Shi, Y., Tarte, K., & Sensebe, L. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.010 · Cited by 464
Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues
Yoo, K. H., Jang, I. K., Lee, M. W., Kim, H. E., Yang, M. S., Eom, Y., Lee, J. E., Kim, Y. J., Yang, S. K., Jung, H. L., et al. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.06.010 · Cited by 416
Bianco, P. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013132 · Cited by 402
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Bouffi, C., Bony, C., Courties, G., Jorgensen, C., & Noël, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014247 · Cited by 383
Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells
Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010) · Stem Cells · doi:10.1002/stem.459 · Cited by 376
ter Huurne, M., Schelbergen, R., Blattes, R., Blom, A., de Munter, W., Grevers, L. C., Jeanson, J., Noël, D., Casteilla, L., Jorgensen, C., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34626 · Cited by 364
Mesenchymal stromal cell ‘licensing’: a multistep process
Krampera, M. (2011) · Leukemia · doi:10.1038/leu.2011.108 · Cited by 358
The stem cell secretome and its role in brain repair
Drago, D., Cossetti, C., Iraci, N., Gaude, E., Musco, G., Bachi, A., & Pluchino, S. (2013) · Biochimie · doi:10.1016/j.biochi.2013.06.020 · Cited by 348
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Manufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Duijvestein, M., Wildenberg, M. E., Welling, M. M., Hennink, S., Molendijk, I., van Zuylen, V. L., Bosse, T., Vos, A. C. W., de Jonge-Muller, E. S. M., Roelofs, H., et al. (2011) · Stem Cells · doi:10.1002/stem.698 · Cited by 330
Regmi, S., Pathak, S., Kim, J. O., Yong, C. S., & Jeong, J.-H. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.04.002 · Cited by 314
Therapeutic Applications of Mesenchymal Stromal Cells: Paracrine Effects and Potential Improvements
Doorn, J., Moll, G., Le Blanc, K., van Blitterswijk, C., & de Boer, J. (2012) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2011.0488 · Cited by 307
Concise Review: Mesenchymal Stem Cells and Translational Medicine: Emerging Issues
Ren, G., Chen, X., Dong, F., Li, W., Ren, X., Zhang, Y., & Shi, Y. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0019 · Cited by 307
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
English, K., French, A., & Wood, K. J. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.009 · Cited by 303
LI, X., BAI, J., JI, X., LI, R., XUAN, Y., & WANG, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1821 · Cited by 301
Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies
Griffin, M. D., Ritter, T., & Mahon, B. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.156 · Cited by 289
Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ
Kim, D. S., Jang, I. K., Lee, M. W., Ko, Y. J., Lee, D.-H., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.002 · Cited by 287
Di Trapani, M., Bassi, G., Midolo, M., Gatti, A., Takam Kamga, P., Cassaro, A., Carusone, R., Adamo, A., & Krampera, M. (2016) · Scientific Reports · doi:10.1038/srep24120 · Cited by 285
The Role of the Immune Cells in Fracture Healing
Baht, G. S., Vi, L., & Alman, B. A. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0423-2 · Cited by 275
Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy
Krampera, M., & Le Blanc, K. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.006 · Cited by 260
The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy
Hoogduijn, M. J., Popp, F., Verbeek, R., Masoodi, M., Nicolaou, A., Baan, C., & Dahlke, M.-H. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.06.019 · Cited by 248
CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties
Yang, Z. X., Han, Z.-B., Ji, Y. R., Wang, Y. W., Liang, L., Chi, Y., Yang, S. G., Li, L. N., Luo, W. F., Li, J. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059354 · Cited by 225
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Mesenchymal stromal cells: promising treatment for liver cirrhosis
Yao, L., Hu, X., Dai, K., Yuan, M., Liu, P., Zhang, Q., & Jiang, Y. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03001-z · Cited by 71
Grau-Vorster, M., Laitinen, A., Nystedt, J., & Vives, J. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1279-9 · Cited by 61
Shafiee, A., Patel, J., Yi Wong, H., Donovan, P., Hutmacher, D. W., Fisk, N. M., & Khosrotehrani, K. (2017) · The FASEB Journal · doi:10.1096/fj.201600937 · Cited by 47
Lee, E.-S., Lim, J.-Y., Im, K.-I., Kim, N., Nam, Y.-S., Jeon, Y.-W., & Cho, S.-G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138846 · Cited by 34
Paladino, F. V., Sardinha, L. R., Piccinato, C. A., & Goldberg, A. C. (2017) · Stem Cells International · doi:10.1155/2017/8492797 · Cited by 23
Engineering islets from stem cells: The optimal solution for the treatment of diabetes
Du, S., Li, Y., Geng, Z., Zhang, Q., Buhler, L. H., Gonelle-Gispert, C., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869514 · Cited by 9
Metadata
- Authors
- Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., & Bartholomew, A.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2008-05-20
- Volume
- 38
- Issue
- 6
- Pages
- 1745-1755
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2045080708
- Cited by
- 581
- References
- 59
- FWCI
- 16.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.